Should Orphan Drug Exclusivity Be Reformed to Lower Prices, Even If It Reduces R&D Incentives? — Rare Diseases Moderator on InVastor
Should Orphan Drug Exclusivity Be Reformed to Lower Prices, Even If It Reduces R&D Incentives? The US Orphan Drug Act grants seven years of market exclusivity for drugs treating rare diseases (affec